Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

901.O1.8 Benign Hematology

Monday, December 8, 2008: 7:00 AM-9:00 AM
2006-2008 - West (Moscone Center)
Moderators:
Richard Lottenberg, MD and Julie A. Panepinto, MD, MSPH
7:00 AM
Acute Care Visits in Sickle Cell Disease: a Population-Based Multi-State Study

David Brousseau, MD, MS1, Julie A. Panepinto, MD, MSPH2, Pamela Owens, PhD3* and Claudia Steiner, MD, MPH3*

1Medical College of Wisconsin/Children's Research Institute of the Children's Hospital of Wisconsin, Milwaukee, WI
2The Medical College of Wisconsin/Children's Research Institute of the Children's Hospital of Wisconsin, Milwaukee, WI
3Agency for Healthcare Research and Quality, Rockville, MD

7:15 AM
Quality of Care in Hospitalizations for Sickle Cell Disease in the U.S.: Do Low Patient Volumes Mean Higher Mortality?

Timothy L McCavit, MD1, Song Zhang, Ph.D.2*, Chul Ahn, Ph.D.2*, Glenn Flores, M.D.1* and Charles T Quinn, M.D.1

1Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX
2Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX

7:30 AM
Adherence with Hydroxyurea in Children with Sickle Cell Disease

Courtney D. Thornburg, MD, MS1, Agustin Calatroni, MS2*, Brittany Herzberg1*, Marilyn J. Telen, MD3 and Alex Kemper, MD, MPH, MS1*

1Pediatrics, Duke University Medical Center, Durham, NC
2Rho, Inc., Chapel Hill, NC
3Medicine, Duke University Medical Center, Durham, NC

7:45 AM
Examining Decision Making Styles in Patients with Sickle Cell Disease (SCD) Regarding Allogeneic Stem Cell Tranplantation (ASCT)

Olabunmi A. Agboola1*, Pareen J. Shenoy, MBBS, MPH2*, Paula J. Edwards, Ph.D.3*, James R. Eckman, MD2* and Christopher R. Flowers, MD2

1College of Medicine, University of Illinois at Chicago, Riverdale, IL
2Winship Cancer Institute, Emory University, Atlanta, GA
3Health Systems Institute, Georgia Institute of Technology, Atlanta

8:00 AM
Clinical and Economic Outcomes Following Full or Partial ACCP Recommended Prophylaxis in Cancer Patients at Risk of Venous Thromboembolism

Alpesh Amin, MD, MBA, FACP1*, Jay Lin, PhD, MBA2*, Guiping Yang3* and Steve Stemkowski, MHA3*

1Division of General Internal Medicine, Department of Medicine, University of California, Irvine, Associate Clinical Professor, Orange, CA
2sanofi-aventis US, Inc., Bridgewater, NJ
3Premier Inc, Charlotte, NC

8:15 AM
Alignment to ACCP Prophylaxis Guidelines and VTE Outcomes in THR and TKR Patients

Bijan Borah, PhD1*, Heather McDonald, MSc2*, Joe Henk, PhD1*, Mark A. Crowther, MD3, Rita Selby, MD4 and Philip Wells, MD, FRCPC, MSc5

1i3Innovus, Eden Prairie, MN
2Bayer Inc, Toronto, ON, Canada
3St. Joseph's Hospital and McMaster University, Hamilton, Canada
4Medicine, Sunnybrook Health Sciences Center, Toronto, ON, Canada
5Ottawa Hospital Civic Site, Ottawa, ON, Canada

8:30 AM
Impact of Surgery Type and Co-Morbidities on Venous Thromboembolism prophylaxis Practices in Patients Undergoing Major Surgical Procedures in Acute Care Hospitals Worldwide: A Subanalysis of Data from the ENDORSE Survey

Ajay K Kakkar, Prof., PhD1, Alexander T Cohen, MBBS, MSc, MD, FRACP2*, Victor F Tapson, MD3*, Jean-Francois Bergmann, Prof., MD4*, Samuel Z. Goldhaber, Prof., MD5 and Frederick A Anderson Jr., PhD6

1Barts and The London School of Medicine, London, United Kingdom
2Department of Vascular Surgery, King's College Hospital, London, United Kingdom
3Duke University Medical Center, Durham, NC
4Hôpital Lariboisiere, University Paris, Paris, France
5Brigham & Women's Hospital, Boston, MA
6Center for Outcomes Research, Univ. of Mass. Medical School, Worcester, MA

8:45 AM
Venous Thromboembolism Risk Model Predicts Early Progression and Overall Mortality in Cancer Patients Receiving Chemotherapy

Nicole M. Kuderer, MD1, Alok A. Khorana, MD2*, Charles W. Francis, MD2, Eva Culakova, PhD, MS1, Thomas L. Ortel, MD, PhD1, Anna Falanga, MD3 and Gary H. Lyman, MD, MPH4

1Duke University, Durham, NC
2University of Rochester Medical Center, Rochester, NY
3SIMT-Thromb. & Hemostasis Ctr., Ospedali Riuniti di Bergamo, Bergamo, Italy
4Medicine, Duke University, Durham, NC

*signifies non-member of ASH